Tag: practice

Los Angeles-based coach and bestselling author Lainie Etzioni has launched The Unbecoming Method, a coaching practice built on one central truth: the survival strategies...

Following a six-month pilot, VetRec becomes VEG's official AI scribe partner, now live across more than 70% of VEG hospitals.WHITE PLAINS, N.Y., June 11,...

BANGALORE, India, June 11, 2026 /PRNewswire/ --  ...

Enhanced platform reflects continued momentum, user-informed innovation and growing adoption among attorneysBUFFALO, N.Y. and TALLAHASSEE, Fla., June 11, 2026 /PRNewswire/ -- M&T Bank (NYSE:MTB)...

FIRST-EVER FDA-CLEARED PERSONALIZED CLINICAL TREATMENT SYSTEM FOR POST-TRAUMATIC STRESS DISORDER (PTSD) ESTABLISHES A NEW CATEGORY IN PRECISION MENTAL HEALTHCARENEWPORT BEACH, Calif., June 11, 2026...

CDP to become two separate organisations – CDP, a commercial entity backed by Permira, and CDP Foundation, a non-profit, charitable organisation focused on pioneering...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

CARPL.ai and Enlitic partner to accelerate imaging AI validation through structured, searchable imaging data for healthcare organizations.

NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026 in the securities class action first filed by the Firm.

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

In the news release, The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical...